title: Imipramine-induced antinociception in the formalin test. Receptor mechanisms involved and effect of swim stress.
abstract: This study concerned the effect of swim stress on imipramine-induced antinociception in mice. The data showed that intraperitoneal (i.p.) administration of different doses of imipramine (10-40 mg/kg) and 0.5-3 min of swim stress (17 degrees C) induced antinociception in the first and second phases of the formalin test. Low period of swim stress (10 s) with low doses of imipramine (2.5, 5 and 10 mg/kg i.p.), which did not have any effect by themselves, in combination showed antinociception in the second phase of the test. Either yohimbine (0.5 mg/kg i.p.) or naloxone (1 mg/kg i.p.) reversed the response induced by the combination of low doses of imipramine plus swim stress. Yohimbine (1 mg/kg i.p.) decreased the response of imipramine (20 mg/kg i.p.) but not that of 30 s swim stress in the second phase. However, naloxone (1 mg/kg i.p.) reduced the antinociception induced by imipramine (20 mg/kg i.p.) or 30 s swim stress in the second phase of the test, the combination of imipramine with swim stress was not altered by yohimbine or naloxone. Prazosin induced antinociception by itself in the first phase of the test and increased swim-stress-induced antinociception with no interaction. It is concluded that antinociception induced by imipramine in the second phase of formalin test may be mediated through alpha(2)-adrenoceptor antagonists. The results indicate that the responses of swim stress and imipramine may be mediated by an opioid mechanism, but the combination of both drugs induced higher antinociceptive effects.
authors.affiliation: Department of Pharmacology, School of Medicine, Tehran University of Medical Science, Tehran, Iran. zarinmr@ams.ac.ir
authors.forename: Mohammad-Reza
authors.initials: MR
authors.lastname: Zarrindast
authors.forename: Nasim
authors.initials: N
authors.lastname: Vousooghi
authors.forename: Mousa
authors.initials: M
authors.lastname: Sahebgharani
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D007099:Imipramine / Q000008:administration & dosage / Q000494:pharmacology*; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009270:Naloxone / Q000494:pharmacology; D009619:Nociceptors / Q000378:metabolism*; D010146:Pain / Q000150:complications* / Q000517:prevention & control*; D010147:Pain Measurement; D011224:Prazosin / Q000494:pharmacology; D013312:Stress, Physiological / Q000150:complications* / Q000503:physiopathology*; D013550:Swimming / Q000502:physiology; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D015016:Yohimbine; D009270:Naloxone; D007099:Imipramine; D011224:Prazosin